Sab biotherapeutics to present novel human igg platform with positive data and breakthrough therapy and fast-track designations for influenza treatment at bio 2023 international convention

Sab biotherapeutics president & chief executive officer eddie sullivan, ph.d. to present novel diversitab™ platform pipeline, with emphasis on partnering influenza therapeutic, sab-176 sab biotherapeutics president & chief executive officer eddie sullivan, ph.d. to present novel diversitab™ platform pipeline, with emphasis on partnering influenza therapeutic, sab-176
SABS Ratings Summary
SABS Quant Ranking